LOW-DOSE GONADOTROPIN THERAPY FOR INDUCTION OF OVULATION IN 100 WOMEN WITH POLYCYSTIC-OVARY-SYNDROME

被引：152

作者：

HAMILTONFAIRLEY, D

KIDDY, D

WATSON, H

SAGLE, M

FRANKS, S

机构：

[1] Department of Obstetrics and Gynaecology, St Mary's Hospital Medical School, London W2 IPG, Norfolk Place

来源：

HUMAN REPRODUCTION | 1991年 / 6卷 / 08期

关键词：

LOW-DOSE GONADOTROPIN; MULTIPLE PREGNANCY; PCOS;

D O I：

10.1093/oxfordjournals.humrep.a137491

中图分类号：

R71 [妇产科学];

学科分类号：

100211 ;

摘要：

Women with anovulation due to polycystic ovary syndrome are likely to develop multiple follicles during gonadotrophin therapy and therefore have a high risk of multiple pregnancy. We have developed a low-dose regimen for use in these women; 100 women with clomiphene-resistant polycystic ovary syndrome were treated. Ninety-five of the women ovulated at least once, 72% of the 401 cycles induced were ovulatory and the majority (73%) of these were uni-ovulatory. The overall cumulative conception rate was 55% at 6 months with only two multiple pregnancies. The rate of early pregnancy loss was 32%, which is similar to that reported by other groups. The prevalence of complications was low with no cases of severe hyperstimulation and < 5% of cycles were abandoned because of development of multiple follicles. Analysis of baseline and mid-follicular luteinizing hormone levels showed that a raised baseline and/or mid-follicular luteinizing hormone level was associated with a poor response to treatment, i.e. anovulation, ovulation but no conception, or early pregnancy loss. There were no successful pregnancies in the women whose luteinizing hormone levels were persistently raised during ovulatory cycles. Low-dose gonadotrophin therapy is a safe and effective method of inducing ovulation; it is associated with a high incidence of single follicular development and a very low multiple pregnancy rate.

引用

页码：1095 / 1099

页数：5

共 32 条

[1]

Adams J., Franks S., Poison D.W., Mason H.D., Abdulwahid N., Tucker M., Morris D.V., Price J., Jacobs H.S., Multifollicular ovaries: Clinical and endocrine features and response to pulsatile gonadotrophin releasing hormone, Lancet, Li, pp. 1375-1378, (1985)

[2]

Adams J., Poison D.W., Franks S., Prevalence of polycystic ovaries in women with anovulation or idiopathic hirsutism, Br. Med. J, 293, pp. 355-359, (1986)

[3]

Brown J.B., Evans J.H., Adey F.D., Taft H.P., Townsend L., Factors involved in the induction of fertile ovulation with human gonadotrophins, J. Obstet. Gynaecol. Br. Common W, 76, pp. 289-306, (1969)

[4]

Buckler H.M., Phillips S.E., Kovecs G.T., Burger H.G., Heely D.L., GnRH agonist administration in Polycystic Ovarian Syndrome, Clin. Endocrinol, 31, pp. 151-165, (1989)

[5]

Buvat J., Buvat-Herbaut M., Marcolin G., Dehaene J.L., Verbecq P., Renovard O., Purified follicle stimulatory hormone in polycystic ovary syndrome

[6]

slow administration is safer and more effective, Fertil. Steril, 52, pp. 553-538, (1989)

[7]

Charbonnel B., Krempf M., Blanchard P., Dano E., Delage C., Induction of ovulation in polycystic ovary syndrome with a combination of a luteinizing hormone releasing analog and endogenous gonadotrophins, Fertil. Steril, 47, pp. 920-924, (1987)

[8]

Coutts J., The use of LHRH analogues in ovulation induction of multiple follicular growth for in vitro fertilization, Wright, London, pp. 198-213, (1989)

[9]

Dor J., Itzkovic D.G., Mashiach S., Lunenfeld B., Serr D.M., Cumulative conception rate following gonadotrophin therapy, Am. J. Obstet. Gynecol, 136, pp. 102-105, (1980)

[10]

Ellis J.D., Williamson J.G., Factors influencing the pregnancy and complication rates with human menopausal gonadotrophin therapy, Br. J. Obstet. Gynaecol, 82, pp. 52-57, (1975)

← 1 2 3 4 →